Healthy Skepticism Library item: 6349

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lee YH, Ji JD, Song GG.
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Rheumatol Int. 2006 Oct 19;

Abstract:

To compare the magnitude of celecoxib versus rofecoxib on the cardiovascular
risk. We performed adjusted indirect comparison of celecoxib versus
rofecoxib
for cardiovascular events using two data on The Adenomatous Polyp Prevention
on
Vioxx (APPROVe) trial and Adenoma Prevention with Celecoxib (APC) trial.
Baseline characteristics of the patients and placebos were comparable in
both
trials, in terms of age, sex, hypertension, diabetes mellitus, smoking, and
hypercholesterolemia. The overall incidence of cardiovascular events was
similar
in both groups (rofecoxib 48/1,287 versus celecoxib 48/1,356, p = 0.79). The
relative risks (RRs) of all myocardial infarction or sudden death from
cardiac
causes were increased in both rofecoxib and celecoxib groups [rofecoxib
versus
placebo; RR 1.35, 95% confidence interval (CI) 1.07-1.69, p = 0.03,
celecoxib
versus placebo; RR 1.35, 95% CI 1.14-1.51, p = 0.01]. The RRs for
cardiovascular
events derived from the adjusted indirect comparisons of the two coxibs did
not
significantly differ from unity (celecoxib versus rofecoxib; RR 0.95, 95% CI
0.76-1.19, p = 0.67). The adjusted indirect comparison analysis shows that
celecoxib and rofecoxib may have similarly effect of cardiovascular events
when
used for 3 years.